GLAXOSMITHKLINE PLC (GSK)

GLAXOSMITHKLINE PLC (GSK)

Seminars

Shareholder Engagement Meeting GSK plc (GSK), London, February 2020

GSK, formerly GlaxoSmithKline, is a global healthcare company that has undergone some significant changes under new leadership over the last 3 years creating a group with 2 leading companies: A world leading Consumer Healthcare company; and a global Pharmaceutical & Vaccines company.

ShareSoc Visit to GSK, June 2019

Blog posts

Market Trends, Interest Rates, Glaxo and Yu Group Accounts

Yesterday was another dismal day in the markets. The US fell significantly allegedly caused by the rise in interest rates announced by the Federal Reserve and the UK market followed it down this morning. The US rate rise was widely expected although perhaps slightly lower estimates for US economic growth had an impact. But when the markets are in a bear mood, excuses for selling abound. Meanwhile the Bank of England has announced today that their base rate will remain at ...

Who are the Election Winners and Losers?

Who are the General Election winners and losers? Well most investors have benefited because the market as a whole has risen today after the election results gave the Conservatives an unexpected victory. Specific sectors that benefited were house builders and utility companies. House builders were generally up at the time of writing this note, with Berkeley Group in particular up 10% - no doubt investors being relieved there would be no mansion tax affecting expensive properties in London.  Utility companies were ...

2014 Review and New Year Resolutions

Now's the time of year to look back on the performance of the stock market in 2014, and look at plans for the future. Last year was undoubtedly a disappointing year for the UK stock market. The FTSE All-Share index was down 2.45%, worse than many other major markets. The cause was undoubtedly that the All-Share index is dominated by large mega-cap FTSE-100 companies such as BP, Shell, Glaxo and Tesco. The first two have been badly hit by the decline ...

Glaxo Q3 results – in need of more treatment

GlaxoSmithKline (GSK) issued its 3rd Quarter Results today (22 Oct 2014). It's one of those large FTSE-100 stocks that it's difficult to avoid holding if you are a UK stock market investor. It's such a large constituent of the index that all those index funds, and indeed almost all generalist unit or investment trusts, are likely to have a big stake in them. It's also one of those stocks that many people hold directly (as does this writer) simply as a ...

High pound also impacts Renishaw and GlaxoSmithKline

Following on from my blog post a couple of days ago about the high pound impacting the profits of technology companies, yesterday saw final results from Renishaw (RSW) and interims from GlaxoSmithKline (GSK) which reflected the same issue. However, the currency impact in both companies was not the main impact on the subsequent share price move. At Renishaw, profits would have been £6.8m higher on top of an "adjusted" figure of £70.1m for the year, but for the currency impact. Last years ...

AGM Reports

GlaxoSmithKline (GSK) AGM 2016

As usual it was an afternoon meeting at 2:30 pm in the Queen Elizabeth II Conference Centre, with one of the biggest audiences I have ever seen there. All the overflow areas were also full. This is one of our biggest companies, with a turnover this year of £23.9bn (£223.0bn) and a total profit declared at £10.3bn (£3.6bn). Sir Phillip Hampton, the new Chairman, appointed 1st January this year, opened the meeting on time. He started positively, emphasising the tremendous reorganisation which ...

GlaxoSmithKline Plc (GSK) AGM 2015

The following report is shorter than usual due to the AGM containing very little of substance, highlighting the difficulty a large FTSE company has in running such an event. On Thursday the 7th of May I attended the Annual General Meeting of GlaxoSmithKline Plc at the QEII Conference Centre, London at 2.30pm. The meeting was attended by about 600 shareholders, less than last year, probably due to the general election being on the same day. On my entry to the building I ...

GlaxoSmithKline Plc (GSK) AGM Report 2014

On Wednesday the 7th of May I attended the Annual General Meeting of GlaxoSmithKline Plc at the QEII Conference Centre, London at 2.30pm. The meeting was well attended with well over 1000 shareholders present, more than GSK originally anticipated as more chairs were called for as the room quickly filled up. Results were in line with expectations at £26.5bn turnover and £8bn core operating profit. After quickly perusing the 251 page report (then putting it on the floor, due the weight of ...

GlaxoSmithKline (GSK) AGM 2013 – a subdued affair

It was an afternoon meeting, at 2:30 pm in the Queen Elizabeth 11 Conference Centre, with a somewhat smaller audience than I have seen in earlier years. This is one of our biggest companies, with a turnover this year of £26.4bn (£27.4bn) and a total profit declared at £7.4bn (£7.8bn). We note with some approval that executive director’s remuneration was down from £11.4m to £8m to £16.2m and total directors’ remuneration from £16.2m to £10.7m, and the latter two figures each ...

Corporate Remuneration Reports

GlaxoSmithKline Remuneration Report 2016

Attached is the Manifest Report. Manifest Executive Remuneration Assessment grade 'D’ (on scale A =good to F=awful) Manifest has assessed the Company’s disclosures against the recommendations of the UK Corporate Governance Code, institutional investor guidelines and the disclosure requirements set out in both the Companies Acts and the UKLA Listing Rules. The following items have been identified which may be of interest to shareholders: Remuneration policy fails to establish a strong degree of alignment between executive remuneration and KPIs/Company strategy. Total ...